Exagen (NASDAQ:XGN) Issues Earnings Results

Key Points

• Exagen reported earnings of ($0.18) EPS, matching analysts' estimates, while facing a negative net margin of 27.34%.
• The company's stock has a market cap of $157.41 million and has experienced significant price fluctuations, with a 52-week low of $1.78 and a high of $7.95.
• Analysts maintain a consensus “Buy” rating for Exagen, with price targets ranging from $7.00 to $12.00 per share.

Exagen (NASDAQ:XGN - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share for the quarter, meeting the consensus estimate of ($0.18), Zacks reports. The firm had revenue of $17.20 million for the quarter, compared to analyst estimates of $16.25 million. Exagen had a negative net margin of 28.85% and a negative return on equity of 130.38%. Exagen updated its FY 2025 guidance to EPS.

Exagen Stock Up 2.7%

XGN stock traded up $0.23 during mid-day trading on Friday, hitting $8.63. 282,684 shares of the company were exchanged, compared to its average volume of 232,041. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.32 and a current ratio of 4.95. The firm has a market cap of $189.89 million, a P/E ratio of -9.70 and a beta of 1.58. The firm's 50 day simple moving average is $7.15 and its 200 day simple moving average is $5.39. Exagen has a 1-year low of $1.78 and a 1-year high of $9.10.

Wall Street Analyst Weigh In

Several analysts recently issued reports on XGN shares. Craig Hallum started coverage on shares of Exagen in a report on Wednesday, July 23rd. They set a "buy" rating and a $12.00 price objective for the company. KeyCorp raised shares of Exagen from a "sector weight" rating to an "overweight" rating and set a $12.00 price objective for the company in a report on Wednesday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $10.00 price objective on shares of Exagen in a report on Wednesday. Canaccord Genuity Group upped their price objective on shares of Exagen from $8.00 to $11.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, BTIG Research reaffirmed a "buy" rating on shares of Exagen in a report on Wednesday, May 7th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $11.25.

Institutional Trading of Exagen

A hedge fund recently bought a new stake in Exagen stock. Acadian Asset Management LLC bought a new position in shares of Exagen Inc. (NASDAQ:XGN - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,984 shares of the company's stock, valued at approximately $25,000. 75.25% of the stock is currently owned by institutional investors and hedge funds.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).